-
Sep 1, 2024 | 
healio.com | Katie Kalvaitis |Erik Swain |Paul M. Ridker |Roger S. Blumenthal
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Cardiovascular disease remains underdiagnosed and undertreated in women. New research stresses the importance of evaluating lifelong risk beyond traditional shorter-term estimates of risk.
-
Jun 24, 2024 | 
arthritis-research.biomedcentral.com | Katherine P Liao |Pamela M Rist |Jon Giles |Leah M. Santacroce |Margery A Connelly |Robert J Glynn | +4 more
The overall study design and the primary results of the TARGET study have been previously published [24, 25]. Briefly, the trial included 138 RA patients, men ≥45 years of age and women ≥50 years of age with a disease activity score 28 with CRP (DAS28-CRP) > 3.2 (moderate disease activity). All subjects must have been treated with MTX ≥15 mg once a week at a stable dose for ≥ 4 weeks prior to their screening visit (or ≥7.5 mg once a week for ≥8 weeks with documented intolerance).
-
Jun 24, 2024 | arthritis-research.biomedcentral.com | Katherine P Liao |Pamela M Rist |Jon Giles |Leah M. Santacroce |Margery A Connelly |Robert J Glynn | +4 more
The overall study design and the primary results of the TARGET study have been previously published [24, 25]. Briefly, the trial included 138 RA patients, men ≥45 years of age and women ≥50 years of age with a disease activity score 28 with CRP (DAS28-CRP) > 3.2 (moderate disease activity). All subjects must have been treated with MTX ≥15 mg once a week at a stable dose for ≥ 4 weeks prior to their screening visit (or ≥7.5 mg once a week for ≥8 weeks with documented intolerance).
-
Jun 24, 2024 | arthritis-research.biomedcentral.com | Katherine P Liao |Pamela M Rist |Jon Giles |Leah M. Santacroce |Margery A Connelly |Robert J Glynn | +4 more
The overall study design and the primary results of the TARGET study have been previously published [24, 25]. Briefly, the trial included 138 RA patients, men ≥45 years of age and women ≥50 years of age with a disease activity score 28 with CRP (DAS28-CRP) > 3.2 (moderate disease activity). All subjects must have been treated with MTX ≥15 mg once a week at a stable dose for ≥ 4 weeks prior to their screening visit (or ≥7.5 mg once a week for ≥8 weeks with documented intolerance).
-
Mar 14, 2024 | 02878-7/fulltext&sz=64)
thelancet.com | Paul M. Ridker |Deepak L. Bhatt |Steven Nissen
1Ridker PM Everett BM Thuren T et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 377: 1119-1131 and of colchicine2Tardif JC Kouz S Waters DD et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med.
-
Oct 23, 2023 | 
healio.com | Paul M. Ridker |Richard Smith
You've successfully added Cardiology: Vascular Medicine to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways:Patients with elevated levels of high-sensitivity C-reactive protein are at risk for CV events.
-
Oct 2, 2023 | 
ahajournals.org | Paul M. Ridker
Privacy Preference CenterWhen you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device. Because we respect your right to privacy, you can choose not to allow certain types of cookies on our website. Click on the different category headings to find out more and manage your cookie preferences.
-
Aug 13, 2023 | 
jacc.org | Kyle Nelson |Valentín Fuster |Paul M. Ridker
References1. "New and emerging therapies for reduction of LDL-cholesterol and apolipoprotein B: JACC focus seminar". J Am Coll Cardiol . 2021;77:1564-1575. 2. "The dawn of a new era of targeted lipid-lowering therapies". Eur Heart J . 2022;43:3198-3208. 3. "Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin". Eur Heart J . 2016;37:1720-1722. 4.
-
Aug 8, 2023 | 
medscape.com | Michelle L. O'Donoghue |Paul M. Ridker
This transcript has been edited for clarity. Michelle L. O'Donoghue, MD, MPH: Hi. This is Dr Michelle O'Donoghue, reporting for Medscape. Joining me today is Dr Paul Ridker. He's the Eugene Braunwald Professor of Medicine at Harvard Medical School. He's also the director of the cardiovascular prevention program at Brigham and Women's Hospital. He's going to be joining me today to discuss a very important and emerging topic, which is the use of low-dose colchicine.
-
Mar 6, 2023 | 00215-5/abstract&sz=64)
thelancet.com | Paul M. Ridker |Robert J Glynn |Jean G MacFadyen |Steven Nissen
Cookie Preference CenterWe use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our Cookie Policy and the list of Google Ad-Tech Vendors. You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer.
